Healthcare Industry News: Non-Small Cell Lung Cancer
News Release - February 18, 2015
Biodesix Builds on Investments in Sales, Reimbursement and Government Affairs Growth StrategyWendy Blosser Will Join Company as VP, Sales; Robin Harper Cowie Promoted to Vice President, Reimbursement and Health Economics; Jasmine Gruia-Gray Becomes Vice President, Marketing
BOULDER, Colo.--(Healthcare Sales & Marketing Network)--Biodesix, Inc. today announced several changes in its commercial operations intended to support rapid growth and payer adoption of its growing portfolio of products targeting lung cancer. Wendy Blosser is joining the company, and will serve as Vice President, Sales driving the sales of Biodesix’ expanding portfolio of blood-based tests in oncology. In addition, two other leaders have stepped into newly created roles: Jasmine Gruia-Gray, PhD. has assumed management of all marketing activities as the Vice President of Marketing and Robin Cowie has been promoted to the newly created role of Vice President, Reimbursement and Health Care Economics.
Biodesix CEO David Brunel noted that, “We are tremendously excited to have Wendy, a proven sales executive with an impressive track record, driving adoption of diagnostics testing in oncology. With VeriStrat® having been adopted into the NCCN Guidelines® and with additional VeriStrat indications and new products slated for release in 2015, we have also expanded the roles of Robin and Jasmine to facilitate payer and clinical adoption.”
Ms. Blosser is an oncology industry veteran who most recently held the position of US Vice President of Sales at Integrated Oncology, a subsidiary of Laboratory Corporation of America, and the world’s largest specialized oncology laboratory. She also led the sales teams at Vermillion Inc., and at Precision Therapeutics, Inc. (now Helomics Corporation,) where she focused predominantly on working with oncology surgeons and radiation oncologists. Ms. Blosser holds an MS from West Virginia University and a BS from Marietta College.
Ms. Cowie joined Biodesix in 2011 as the company’s first director of reimbursement. Ms. Cowie’s previous experience in reimbursement, payer and government affairs came during several years at Precision Therapeutics, Inc. (now Helomics Corporation,) a personalized healthcare company where she created and launched the company’s successful payer strategy. She has a BS in molecular genetics and an MBA from the University of Pittsburgh.
Dr. Gruia-Gray joined Biodesix in 2014. Previously, she held the position of Vice President, Global Marketing at Affymetrix, Inc., a leading provider of genomics analysis using microarray technology, and at Dionex (now ThermoFisher Scientific) and GE Healthcare. Dr. Gruia-Gray has extensive leadership experience in the life sciences industry, with a focus on successfully bridging scientific innovation with customer needs. She has a PhD in molecular biology from the University of Toronto.
“With a focus on precision medicine - providing the right patient with the right treatment at the right time – we endeavor to improve the quality of patients’ lives. Our healthcare system is benefiting from the advances made possible by precision medicine, and with the innovations at Biodesix, we intend to be at the forefront of providing clinical utility and payer engagement,” Brunel said.
Biodesix is a molecular diagnostics company advancing the development of innovative products for precision medicine. The company provides physicians with diagnostic tests for earlier disease detection, more accurate diagnosis, disease monitoring and better therapeutic guidance, which may lead to improved patient outcomes. Biodesix discovers, develops and commercializes multivariate protein diagnostics based on their proprietary mass spectrometry-based discovery platform. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve utility of therapeutic agents. For more information about Biodesix, please visit www.Biodesix.com.
VeriStrat, developed by Biodesix, is a multivariate, blood-based, protein test currently available to help physicians guide treatment decisions for patients with advanced Non-Small Cell Lung Cancer. The test identifies patients who are likely to have “Good” or “Poor” outcomes after treatment with either epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy such as erlotinib or with chemotherapy. VeriStrat is based on Biodesix’ proprietary proteomics platform which enables the discovery of multivariate classifiers that characterize a patient’s condition or likely outcome in response to therapy. For more information, please visit www.VeriStratSupport.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.